Published in TB and Outbreaks Week, October 16th, 2007
The funding will be used to develop potent therapeutic mAbs capable of suppressing the toxic effects of SEB with the goal of demonstrating proof-of-concept in clinical trials. By employing Morphotek's proprietary human...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week